Patents by Inventor Patrice Denefle

Patrice Denefle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170183736
    Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
    Type: Application
    Filed: November 4, 2016
    Publication date: June 29, 2017
    Inventors: Alexis Brice, Christophe Lucking, Patrice Denefle, Sylvain Ricard, Nacer Eddine Abbas, Sandrine Bouley
  • Patent number: 9540693
    Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: January 10, 2017
    Assignees: Aventis Pharma S.A., Institut National de la Santé et de la Recherche Médicale
    Inventors: Alexis Brice, Christophe Lucking, Patrice Denefle, Sylvain Ricard, Nacer Eddine Abbas, Sandrine Bouley
  • Publication number: 20150074836
    Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
    Type: Application
    Filed: August 7, 2014
    Publication date: March 12, 2015
    Applicants: Aventis Pharma S.A., Institut National de la Santé et de la Recherche Médicale
    Inventors: Alexis Brice, Christophe Lucking, Patrice Denefle
  • Patent number: 8835618
    Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: September 16, 2014
    Assignees: Aventis Pharma S.A., Institut National de la Santé et de la Recherche Médicale
    Inventors: Alexis Brice, Christophe Lucking, Patrice Denefle, Sylvain Ricard, Nacer Eddine Abbas, Sandrine Bouley
  • Patent number: 8642739
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: February 4, 2014
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrice Denefle, Thomas F. Haws, June M. Kaplow, Marie Rosier
  • Patent number: 8623831
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: January 7, 2014
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrice Denefle, Thomas F. Haws, June M. Kaplow, Marie Rosier
  • Publication number: 20130164262
    Abstract: Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.
    Type: Application
    Filed: August 13, 2012
    Publication date: June 27, 2013
    Inventors: Patrick Benoit, Patrice Denefle, Michel Perricaudet, M.E. Suzanne Lewis, Michael R. Hayden
  • Publication number: 20120064598
    Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
    Type: Application
    Filed: August 15, 2011
    Publication date: March 15, 2012
    Applicants: INSTITUT NATIONAL SANTE ET RECHERCHE MEDICALE, AVENTIS PHARMA S.A.
    Inventors: Alexis Brice, Christophe Lucking, Patrice Denefle, Sylvain Ricard, Nacer Eddine Abbas, Sandrine Bouley
  • Publication number: 20110263831
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Application
    Filed: June 10, 2011
    Publication date: October 27, 2011
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: June KAPLOW, Thomas HAWS, Marie ROSIER, Patrice DENEFLE
  • Publication number: 20110245471
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacutre of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Application
    Filed: June 10, 2011
    Publication date: October 6, 2011
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: June KAPLOW, Thomas HAWS, Marie ROSIER, Patrice DENEFLE
  • Patent number: 7998667
    Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: August 16, 2011
    Assignees: Aventis Pharma S.A., Institut National Sante et Recherche Medicale
    Inventors: Alexis Brice, Christophe Lucking, Patrice Denefle, Sylvain Ricard, Nacer Eddine Abbas, Sandrine Bouley
  • Patent number: 7972844
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: July 5, 2011
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: June Kaplow, Thomas Haws, Marie Rosier, Patrice Denefle
  • Publication number: 20090257981
    Abstract: Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.
    Type: Application
    Filed: May 24, 2007
    Publication date: October 15, 2009
    Inventors: Patrick Benoit, Patrice Denefle, Michel Perricaudet, M.E. Suzanne Lewis, Michael R. Hayden
  • Patent number: 7378274
    Abstract: The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis. The invention also relates to nucleotide constructs comprising a polynucleotide which encodes a polypeptide or a nucleic acid of interest, placed under the control a regulatory nucleic acid for the ABC1 gene. The invention also relates to recombinant vectors, transformed host cells and nonhuman transgenic mammals comprising a nucleic acid which regulates the transcription of the ABC1 gene or an abovementioned nucleotide construct, as well as methods for screening molecules or substances which are capable of modifying the activity of the regulatory nucleic acid for the ABC1 gene.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: May 27, 2008
    Assignee: Aventis Pharma S.A.
    Inventors: Marie-Françoise Rosier-Montus, Catherine Prades, Cendrine Lemoine, Laurent Naudin, Patrice Denefle, Nicolas Duverger, Bryan Brewer, Alan Remaley, Sylvia Santamarina-Fojo
  • Publication number: 20060223771
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacutre of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Application
    Filed: February 15, 2006
    Publication date: October 5, 2006
    Applicant: Aventis Pharmaceuticals Products Inc.
    Inventors: June Kaplow, Thomas Haws, Marie Rosier, Patrice Denefle
  • Patent number: 7041497
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: May 9, 2006
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: June Kaplow, Thomas Haws, Marie Rosier, Patrice Denefle
  • Publication number: 20060063166
    Abstract: The present invention relates to a novel human ABCC12 gene as well as the cDNAs encoding the novel short and long of ABCC12 proteins isoforms. The invention also relates to vectors and recombinant host cells comprising such nucleic acids, nucleotide probes and primers, and means for the detection of polymorphisms and mutations in the ABCC12 gene or in the corresponding proteins isoforms produced by the allelic form of the ABCC12 gene.
    Type: Application
    Filed: December 16, 2004
    Publication date: March 23, 2006
    Applicant: Aventis Pharma S. A.
    Inventors: Marie Rosier, Catherine Prades, Isabelle Arnould, Michael Dean, Rando Allikmets, Patrice Denefle
  • Publication number: 20050163754
    Abstract: Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.
    Type: Application
    Filed: April 26, 2004
    Publication date: July 28, 2005
    Inventors: Patrick Benoit, Patrice Denefle, Michael Perricaudet, M.E. Lewis, Michael Hayden
  • Publication number: 20050158784
    Abstract: The present invention relates to nucleic acids corresponding to various exons of the ABCC11 gene as well as the cDNA encoding the novel full length of ABCC11 protein. The invention also relates to means for the detection of polymorphisms in general, and of mutations in particular, in the ABCC11 gene or in the corresponding protein produced by the allelic form of the ABCC11 gene.
    Type: Application
    Filed: January 12, 2005
    Publication date: July 21, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Marie Rosier, Catherine Prades, Isabelle Arnould, Michael Dean, Rando Allikmets, Patrice Denefle
  • Patent number: 6893841
    Abstract: The present invention relates to nucleic acids corresponding to various exons of the ABCC11 gene as well as the cDNA encoding the novel full length of ABCC11 protein. The invention also relates to means for the detection of polymorphisms in general, and of mutations in particular, in the ABCC11 gene or in the corresponding protein produced by the allelic form of the ABCC11 gene.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: May 17, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Marie Rosier, Catherine Prades, Isabelle Arnould, Michael Dean, Rando Allikmets, Patrice Denefle